56 related articles for article (PubMed ID: 22585164)
1. The 14-3-3σ tumor suppressor has multiple functions in ErbB2-induced breast cancer.
Hynes NE; Smirnova T
Cancer Discov; 2012 Jan; 2(1):19-22. PubMed ID: 22585164
[TBL] [Abstract][Full Text] [Related]
2. Loss of the 14-3-3σ tumor suppressor is a critical event in ErbB2-mediated tumor progression.
Ling C; Su VM; Zuo D; Muller WJ
Cancer Discov; 2012 Jan; 2(1):68-81. PubMed ID: 22585169
[TBL] [Abstract][Full Text] [Related]
3. In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
Basak P; Leslie H; Dillon RL; Muller WJ; Raouf A; Mowat MRA
Genes Chromosomes Cancer; 2018 Apr; 57(4):182-191. PubMed ID: 29218825
[TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Peng M; Ball-Kell SM; Tyner AL
Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
[TBL] [Abstract][Full Text] [Related]
5. β-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
Bui T; Schade B; Cardiff RD; Aina OH; Sanguin-Gendreau V; Muller WJ
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):E707-E716. PubMed ID: 28096336
[TBL] [Abstract][Full Text] [Related]
6. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
[TBL] [Abstract][Full Text] [Related]
7. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
8. β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.
Schade B; Lesurf R; Sanguin-Gendreau V; Bui T; Deblois G; O'Toole SA; Millar EK; Zardawi SJ; Lopez-Knowles E; Sutherland RL; Giguère V; Kahn M; Hallett M; Muller WJ
Cancer Res; 2013 Jul; 73(14):4474-87. PubMed ID: 23720052
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.
Yallowitz AR; Li D; Lobko A; Mott D; Nemajerova A; Marchenko N
Mol Cancer Res; 2015 Apr; 13(4):743-54. PubMed ID: 25573952
[TBL] [Abstract][Full Text] [Related]
10. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.
Guo W; Pylayeva Y; Pepe A; Yoshioka T; Muller WJ; Inghirami G; Giancotti FG
Cell; 2006 Aug; 126(3):489-502. PubMed ID: 16901783
[TBL] [Abstract][Full Text] [Related]
11. PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2.
Dong H; Ma L; Gan J; Lin W; Chen C; Yao Z; Du L; Zheng L; Ke C; Huang X; Song H; Kumar R; Yeung SC; Zhang H
Oncogene; 2017 Jan; 36(3):410-422. PubMed ID: 27345410
[TBL] [Abstract][Full Text] [Related]
12. ErbB2 and p38γ MAPK mediate alcohol-induced increase in breast cancer stem cells and metastasis.
Xu M; Ren Z; Wang X; Comer A; Frank JA; Ke ZJ; Huang Y; Zhang Z; Shi X; Wang S; Luo J
Mol Cancer; 2016 Jul; 15(1):52. PubMed ID: 27416801
[TBL] [Abstract][Full Text] [Related]
13. The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium.
Ip MM; McGee SO; Masso-Welch PA; Ip C; Meng X; Ou L; Shoemaker SF
Carcinogenesis; 2007 Jun; 28(6):1269-76. PubMed ID: 17259656
[TBL] [Abstract][Full Text] [Related]
14. PGC-1α promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply.
Klimcakova E; Chénard V; McGuirk S; Germain D; Avizonis D; Muller WJ; St-Pierre J
Cancer Res; 2012 Mar; 72(6):1538-46. PubMed ID: 22266114
[TBL] [Abstract][Full Text] [Related]
15. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
16. Insights from transgenic mouse models of ERBB2-induced breast cancer.
Ursini-Siegel J; Schade B; Cardiff RD; Muller WJ
Nat Rev Cancer; 2007 May; 7(5):389-97. PubMed ID: 17446858
[TBL] [Abstract][Full Text] [Related]
17. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
18. Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.
Farabaugh SM; Chan BT; Cui X; Dearth RK; Lee AV
Cell Commun Signal; 2016 Oct; 14(1):25. PubMed ID: 27765041
[TBL] [Abstract][Full Text] [Related]
19. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML
Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
